xml version="1.0" encoding="utf-8"?               

   0000882095 false        0000882095   2022-01-05 2022-01-05    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of

 The Securities Exchange Act of 1934 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 5, 2022 

GILEAD SCIENCES, INC. 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

333 Lakeside Drive, Foster City, California 

(Address of Principal Executive Offices) 

94404 

(Zip Code) 

650-574-3000 

(Registrant’s Telephone Number, Including Area Code) 

Not Applicable 

(Former Name or Former Address, if Changed Since Last Report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT 

 Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

(b) Departure of Certain Officers 

On January 6, 2022, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Brett A. Pletcher plans to retire from his position as the Company’s Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary. No formal date has been established for Mr. Pletcher’s retirement, and Mr. Pletcher expects to continue in his role while the Company works to identify a successor and thereafter to assist in the transition, which is expected to occur by the end of summer 2022. 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

Date: January 6, 2022